{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:59:13Z","timestamp":1783702753151,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002670"],"award-info":[{"award-number":["82002670"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"crossref","award":["22ZR1413400"],"award-info":[{"award-number":["22ZR1413400"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Health Bureau Project","award":["202340127"],"award-info":[{"award-number":["202340127"]}]},{"name":"Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation","award":["YJYQ201802"],"award-info":[{"award-number":["YJYQ201802"]}]},{"name":"Shanghai Sailing Program","award":["21YF1407000"],"award-info":[{"award-number":["21YF1407000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14870-x","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:49:38Z","timestamp":1758804578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5288-5037","authenticated-orcid":false,"given":"Zhaopei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8634-520X","authenticated-orcid":false,"given":"Ziyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"1","key":"14870_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2022","unstructured":"Cathomas R, Lorch A, Bruins HM, Comp\u00e9rat EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hern\u00e1ndez V, Espin\u00f3s EL, et al. The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2022;81(1):95\u2013103.","journal-title":"Eur Urol"},{"issue":"10064","key":"14870_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67\u201376.","journal-title":"Lancet"},{"issue":"2","key":"14870_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2011","unstructured":"De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, et al. Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for Cisplatin-Based chemotherapy: EORTC study 30986. J Clin Oncol. 2011;30(2):191\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"14870_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, et al. Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"22","key":"14870_CR5","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fl\u00e9chon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, et al. TROPHY-U-01: a phase II open-label study of sacituzumab Govitecan in patients with metastatic urothelial carcinoma progressing after Platinu m-Based chemotherapy and checkpoint inhibitors. Off J Am Societ Y Clin Oncol. 2021;39(22):2474\u201385.","journal-title":"Off J Am Societ Y Clin Oncol"},{"issue":"16","key":"14870_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED. Disitamab vedotin: first approval. Drugs. 2021;81(16):1929\u201335.","journal-title":"Drugs"},{"issue":"1","key":"14870_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-Targeting Antibody\u2013Drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(1):43\u201351.","journal-title":"Clin Cancer Res"},{"key":"14870_CR8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2023","unstructured":"Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C, et al. Efficacy and safety of disitamab Vedotin in patients with human epidermal growth factor receptor 2\u2013Positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials. J Clin Oncol. 2023;42:1391.","journal-title":"J Clin Oncol"},{"issue":"6suppl","key":"14870_CR9","doi-asserted-by":"publisher","first-page":"TPS594","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS594","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Yu EY, Iyer G, Campbell MT, Loriot Y, De Santis M, O\u2019Donnell PH, Burgess EF, Necchi A, Krieger LEM, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab Vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). J Clin Oncol. 2023;41(6suppl):TPS594\u2013594.","journal-title":"J Clin Oncol"},{"key":"14870_CR10","doi-asserted-by":"publisher","first-page":"978266","DOI":"10.3389\/fimmu.2022.978266","volume":"13","author":"Z Xu","year":"2022","unstructured":"Xu Z, Ma J, Chen T, Yang Y. Case report: the remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma. Front Immunol. 2022;13:978266.","journal-title":"Front Immunol"},{"key":"14870_CR11","doi-asserted-by":"publisher","first-page":"1230395","DOI":"10.3389\/fphar.2023.1230395","volume":"14","author":"Y Wei","year":"2023","unstructured":"Wei Y, Zhang R, Yu C, Hong Z, Lin L, Li T, Chen J. Disitamab Vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center\u2019s real-world study. Front Pharmacol. 2023;14:1230395.","journal-title":"Front Pharmacol"},{"issue":"8","key":"14870_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody\u2013drug conjugates come of age in oncology. Nat Rev Drug Discovery. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"14870_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2022.04.022","volume":"83","author":"A Kartolo","year":"2023","unstructured":"Kartolo A, Robinson A, Vera Badillo FE. Can oncogenic driver alterations be responsible for the lack of immunotherapy efficacy in First-line advanced urothelial carcinoma?? Eur Urol. 2023;83(1):1\u20132.","journal-title":"Eur Urol"},{"issue":"1","key":"14870_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal R, Valderrama BP, Bellmunt J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Reviews Clin Oncol. 2024;21(1):8\u201327.","journal-title":"Nat Reviews Clin Oncol"},{"key":"14870_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"issue":"8","key":"14870_CR16","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","volume":"28","author":"L Zhou","year":"2023","unstructured":"Zhou L, Shao Z, Liu Y, Yan X, Li J, Wu X, Tang B, Li S, Cui C, Chi Z, et al. HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a Chinese population. Oncologist. 2023;28(8):e617\u201324.","journal-title":"Oncologist"},{"issue":"6","key":"14870_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00428-023-03671-x","volume":"484","author":"C Garrido","year":"2024","unstructured":"Garrido C, Manoogian M, Ghambire D, Lucas S, Karnoub M, Olson MT, Hicks DG, Tozbikian G, Prat A, Ueno NT, et al. Analytical and clinical validation of PATHWAY Anti-HER-2\/neu (4B5) antibody to assess HER2-low status for trastuzumab Deruxtecan treatment in breast cancer. Virchows Arch. 2024;484(6):1005\u201314.","journal-title":"Virchows Arch"},{"issue":"22","key":"14870_CR18","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American pathologists guideline update. J Clin Oncol. 2023;41(22):3867\u201372.","journal-title":"J Clin Oncol"},{"key":"14870_CR19","doi-asserted-by":"publisher","first-page":"1095775","DOI":"10.3389\/fonc.2023.1095775","volume":"13","author":"S Tai","year":"2023","unstructured":"Tai S, Xu DD, Yu Z, Guan Y, Yin S, Xiao J, Xue S, Liang C. Genomic profiles of renal cell carcinoma in a small Chinese cohort. Front Oncol. 2023;13:1095775.","journal-title":"Front Oncol"},{"issue":"6","key":"14870_CR20","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00262-022-03347-6","volume":"72","author":"B Fang","year":"2023","unstructured":"Fang B, Wei Y, Zeng H, Li Y, Chen S, Zhang T, Pan J, Wang B, Wu J, Jin S, et al. Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients. Cancer Immunol Immunother. 2023;72(6):1541\u201351.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"14870_CR21","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808\u201325.","journal-title":"Cancer Discov"},{"issue":"7","key":"14870_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jnci\/djt015","volume":"105","author":"AB Apolo","year":"2013","unstructured":"Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013;105(7):499\u2013503.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"14870_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacc.2020.10.046","volume":"77","author":"A Zegard","year":"2021","unstructured":"Zegard A, Okafor O, de Bono J, Kalla M, Lencioni M, Marshall H, Hudsmith L, Qiu T, Steeds R, Stegemann B, et al. Myocardial fibrosis as a predictor of sudden death in patients with coronary artery disease. J Am Coll Cardiol. 2021;77(1):29\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"14870_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27\u201338.","journal-title":"Biometrika"},{"issue":"8","key":"14870_CR25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857\u201372.","journal-title":"Stat Med"},{"issue":"5","key":"14870_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","volume":"28","author":"ES Kim","year":"2022","unstructured":"Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, Chae YK, Leal TA, Dowell JE, Tsai ML, et al. Blood-based tumor mutational burden as a biomarker for Atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat Med. 2022;28(5):939\u201345.","journal-title":"Nat Med"},{"key":"14870_CR27","first-page":"30","volume":"2024","author":"WF Maguire","year":"2011","unstructured":"Maguire WF, Lee D, Weinstock C, Gao X, Bulik CC, Agrawal S, Chang E, Hamed SS, Bloomquist EW, Tang S, et al. FDA approval summary: enfortumab Vedotin plus pembrolizumab for Cisplatin-Ineligible locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2011;2024:30.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"14870_CR28","first-page":"121","volume":"3","author":"H Lei","year":"2023","unstructured":"Lei H, Ling Y, Yuan P, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, et al. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. J Natl Cancer Cent. 2023;3(2):121\u20138.","journal-title":"J Natl Cancer Cent"},{"issue":"2","key":"14870_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"7","key":"14870_CR30","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00262-023-03419-1","volume":"72","author":"M Chen","year":"2023","unstructured":"Chen M, Yao K, Cao M, Liu H, Xue C, Qin T, Meng L, Zheng Z, Qin Z, Zhou F, et al. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunol Immunother. 2023;72(7):2309\u201318.","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"14870_CR31","doi-asserted-by":"publisher","first-page":"21159","DOI":"10.1002\/cam4.6680","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu J, Zhang H, Zhang L, Chu X, Li Y, Li G, Nie C, Wang M, Guo Y. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study. Cancer Med. 2023;12(23):21159\u201371.","journal-title":"Cancer Med"},{"issue":"20","key":"14870_CR32","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper N, Tran NK, Zsch\u00e4bitz S, Hahn O, B\u00fcttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, et al. NECTIN4 amplification is frequent in solid tumors and predicts enfortumab Vedotin response in metastatic urothelial cancer. J Clin Oncol. 2024;42(20):2446\u201355.","journal-title":"J Clin Oncol"},{"issue":"8","key":"14870_CR33","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, Ducoulombier A, Pistilli B, Bachelot T, Viret F, et al. Trastuzumab Deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29(8):2110\u201320.","journal-title":"Nat Med"},{"issue":"1","key":"14870_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12967-025-06082-5","volume":"23","author":"R Huang","year":"2025","unstructured":"Huang R, Hu A, Rong Q, Shu D, Chen M, Yang W, Zhang Y, Zheng Q, An X, Xue C, et al. Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer. J Transl Med. 2025;23(1):63.","journal-title":"J Transl Med"},{"issue":"1","key":"14870_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59\u201373.","journal-title":"Nat Rev Immunol"},{"issue":"10200","key":"14870_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793\u2013804.","journal-title":"Lancet"},{"issue":"6suppl","key":"14870_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1200\/JCO.2023.41.6_suppl.450","volume":"41","author":"T Jindal","year":"2023","unstructured":"Jindal T, Kilari D, Alhalabi O, Nizam A, Khaki AR, Basu A, Barata PC, Bilen MA, Shah S, Zakharia Y, et al. Biomarkers of response to enfortumab Vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): analysis of the UNITE study. J Clin Oncol. 2023;41(6suppl):450\u2013450.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14870_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","volume":"191","author":"L Huang","year":"2022","unstructured":"Huang L, Wang R, Xie K, Zhang J, Tao F, Pi C, Feng Y, Gu H, Fang J. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2\u2009+\u2009tumors in hPD-1 Transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51\u201361.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"14870_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu X, Xu L, Li X, Zhou Y, Han X, Zhang W, Wang W, Guo W, Liu W, Xu Q, et al. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway. Cell Death Dis. 2023;14(8):550.","journal-title":"Cell Death Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14870-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14870-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14870-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:49:39Z","timestamp":1758804579000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14870-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14870"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14870-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Zhongshan Hospital and Fudan University (No. B2024-085). Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1432"}}